Efficacy and Safety of Stanford Accelerated Intelligent Neuromodulation Therapy in Combina-tion with Medication for First-episode Depressive Disorder
[Objective]To investigate the efficacy and safety of Stanford accelerated intelligent neuromodu-lation therapy(SNT)combined with medication in the treatment of first-episode depressive disorder.[Meth-ods]A total of 56 patients with depressive disorder hospitalized in the Hunan Brain Hospital from December 2022 to December 2023 were selected and divided into SNT combined with drug therapy group(SNT group)or repetitive transcranial magnetic stimulation(rTMS)combined with drug therapy group(rTMS group)accord-ing to random number table method,with 28 cases in each group.After 1 week and 4 weeks of treatment,17-item Hamilton Depression Scale(HAMD17)and Hamilton Anxiety Scale(HAMA)were used to evaluate the depression and anxiety symptoms of the patients,and adverse events were recorded by self-designed adverse e-vent record sheet.[Results]After 1 week of treatment and 4 weeks of treatment,HAMDi7 scores and HAMA scores in two groups were lower than before treatment,and HAMD17 scores and HAMA scores in the SNT group were lower than those of the rTMS group after 1 week of treatment,with statistical significance(P＞0.05).After 1 week of treatment,the effective rate of HAMD17 score and HAMA score in the rTMS group was 36％,and that in the SNT group was 100％.The clinical effective rate in the SNT group was higher than that in the rTMS group,with statistical significance(P＜0.05).After 4 weeks of treatment,the effective rates of HAMD17 score and HAMA score in the rTMS group were 96％and 100％,respectively,while those in the SNT group were 100％.There was no statistical significance in the effective rates between the two groups(P＞0.05).[Conclusion]SNT and rTMS are safe and effective in the treatment of first-episode de-pressive disorder.SNT model can significantly improve depression and anxiety symptoms faster than rTMS.
万方数据
维普
